Join our daily newsletter At The Bell to receive exclusive market insights
Synthetic anti-infective developer Recce Pharmaceuticals Ltd (ASX:RCE) has made inroads for recognition of its RECCE® 327 Gel (or R327G) as a topical treatment for burn wound infections, gaining a US$2 million grant from the US Department of Defense to accelerate its development.
The funding will be invested in developing R327G for the specific treatment of these wound infections in a military setting, with the treatment of downstream bacteria complications such as sepsis also a focus.
The company will be aiming to build on this recognition, with this gel to be considered a replacement for traditional antimicrobial dressings and topicals used in this setting, and for other R327G products to be considered applicable to military contexts.
Chief Executive Officer of Recce Pharmaceuticals James Graham said the funding underscored the value of Recce’s developments in this sector.
“We are honoured by the US Department of Defense’s decision to award grant funding for Recce, as it underscores our commitment to advancing medical solutions critical to military personnel,” he said.
“This recognition is a testament to the unique profile of Recce technology and the high quality of R&D conducted.
“We look forward to working closely with the US Department of Defense to progress our research efforts and fulfil our commitment to improving global health outcomes.”
Recce has been trading at 46.5 cents.
